How mRNA Works Moderna

FDA, mRNA and Moderna

FDA panel recommends Moderna’s mRNA flu shot for older adults

A Food and Drug Administration advisory panel on Thursday recommended the approval of Moderna’s mRNA-based flu shot for older adults.

BioPharma Dive · 4d

FDA staff scrutinizes evidence supporting Moderna’s flu vaccine

· 2d · on MSN

FDA panel recommends mRNA flu vaccine for older adults

· 1d

Moderna's mRNA flu vaccine backed by FDA advisers

Advisers to the U.S. Food and Drug Administration on Thursday backed approval of Moderna's (MRNA.O) flu vaccine for adults aged ‌50 and older, saying its benefits outweigh its risks, boosting the comp...

· 1d

First-of-its-kind flu vaccine could be coming as FDA panel weighs historic shot

· 1d

Moderna flu vaccine OK’d by FDA panel

Moderna just got a signal investors can’t ignore

The Food and Drug Administration (FDA) is getting ready to evaluate Moderna’s messenger RNA-based flu shot, MFLUSIVA, Fierce Biotech reported, and the landscape appears more positive than investors might have expected. The problem is larger than a single seasonal vaccine.

13d

How Investors May Respond To Moderna (MRNA) mRNA Advances in Personalized Cancer and Emerging Infectious Diseases

In recent days, Moderna and Merck reported five-year Phase 2b data showing that their personalized mRNA melanoma vaccine intismeran autogene, combined with Keytruda, substantially reduced the risk of cancer recurrence,

Kalkine Media

Why Moderna Is Capturing Market Attention Again?

Moderna stays in focus as its mRNA pipeline keeps drawing attention across biotechnology and the broader healthcare space.

Hosted on MSN

What are mRNA vaccines, and how do they work?

Many people first learned about mRNA vaccines during the coronavirus pandemic, when the companies Pfizer-BioNTech and Moderna released their COVID-19 vaccines. The Pfizer-BioNTech shot was the first COVID-19 vaccine to earn emergency authorization in the ...

Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine

FDA Prescription Drug User Fee Act (PDUFA) goal date remains August 5, 2026 CAMBRIDGE, MA / ACCESS Newswire / June 18, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological

MarketWatch

Moderna’s work developing seasonal vaccines is ‘risky’ under current FDA, analyst says

Moderna’s mRNA-centric business is in conflict with the U.S. government’s shifting views on mRNA technology, and analysts say that’s a risk. The biotech announced Tuesday evening that in a rare move, the Food and Drug Administration won’t review ...